-
Mashup Score: 0ATS Conference 2024 - Learning Studios - 3 hour(s) ago
American Thoracic Society
Source: conference.thoracic.orgCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 0Aberrant Lipid Metabolism in Macrophages Is Associated with Granuloma Formation in Sarcoidosis - 4 hour(s) ago
Rationale: Chronic sarcoidosis is a complex granulomatous disease with limited treatment options that can progress over time. Understanding the molecular pathways contributing to disease would aid …
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 4Medicaid Enrollment and Unwinding Tracker - 4 hour(s) ago
To monitor changes in Medicaid enrollment during the unwinding period, this tracker presents the most recent Medicaid enrollment data available for each state as well as any unwinding data on month…
Source: www.kff.orgCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 2ATS - American Thoracic Society - 5 hour(s) ago
American Thoracic Society
Source: www.thoracic.orgCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 1KFF Health Tracking Poll May 2024: The Public’s Use and Views of GLP-1 Drugs | KFF - 5 hour(s) ago
KFF’s latest Health Tracking Poll examines the public’s views and use of an an increasingly popular class of prescription drugs used for weight loss and to treat diabetes or prevent heart attacks or strokes. The poll finds 12% of adults report having taken one of these GLP-1 drugs, which include Ozempic, Webovy and Mounjaro. This includes 6% who say they are currently taking one of the drugs.
Source: www.kff.orgCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 0Zinpentraxin Alfa for Idiopathic Pulmonary Fibrosis: The Randomized Phase III STARSCAPE Trial - 5 hour(s) ago
Rationale: A phase II trial reported clinical benefit over 28 weeks in patients with idiopathic pulmonary fibrosis (IPF) who received zinpentraxin alfa. Objectives: To investigate the efficacy and …
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 4
Rationale: Diffuse alveolar hemorrhage (DAH) is a life-threatening manifestation of antineutrophil cytoplasmic antibody–associated vasculitis (AAV). The PEXIVAS (Plasma Exchange and Glucocorticoids…
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 2Impact of age at ivacaftor initiation on pulmonary outcomes among people with cystic fibrosis - 6 hour(s) ago
Background Ivacaftor (IVA) improves lung function and other extrapulmonary outcomes in people with cystic fibrosis (CF). However, the effect of initiating IVA at earlier versus later ages has not been studied. Methods We conducted an observational cohort study of people in the US CF Foundation Patient Registry aged ≥6 years with ≥1 CF transmembrane conductance regulator–gating mutation to compare the effects of initiating IVA at earlier ages on per cent predicted forced expiratory volume in 1 s (ppFEV1) and pulmonary exacerbation (PEx) outcomes. People with CF were grouped by age at IVA initiation (ages 6–10, 11–15, 16–20 and 21–25 years) to perform three analyses of younger versus older IVA initiation (6–10 vs 11–15, 11–15 vs 16–20 and 16–20 vs 21–25 years). For each analysis, baseline characteristics assessed over 1-year periods at the same age prior to IVA initiation were balanced by standardised mortality/morbidity ratio (SMR) weighting. For each analysis, outcomes were compared ov
Source: thorax.bmj.comCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 7Upcoming Live-Streamed Health Care Events | NEJM Group - 6 hour(s) ago
NEJM Group offers live web events covering the important topics impacting health care. See our upcoming schedule.
Source: events.nejm.orgCategories: General Medicine News, PulmonologyTweet
-
Mashup Score: 7
Proof that nintedanib and pirfenidone slow progression of idiopathic pulmonary fibrosis (IPF) has sparked further clinical trials that are being pursued in the hope of curing this devastating disease. This includes the study of pentraxin-2, a liver-synthesized plasma protein with antiinflammatory and antifibrotic properties in in vitro and animal models (1). In this issue of the Journal, Richeldi and colleagues (pp. 1132–1140) report findings of the phase III STARSCAPE randomized controlled trial (RCT)
Source: www.atsjournals.orgCategories: General Medicine News, PulmonologyTweet
https://t.co/7qCQ7V1OpJ https://t.co/btv1IWFi59